Moderna (MRNA) - Get Report has cut a deal with Japan to supply at least 40 million doses of its late-stage Covid-19 vaccine candidate, another sign of how countries are looking to stockpile vaccines even before they’re both proven and approved.
In a statement, Moderna confirmed on Friday that it has made preliminary arrangements to supply Japan’s Ministry of Health, Labor and Welfare with 40 million or more doses of its Covid-19 vaccine candidate mRNA-1273, which is currently in stage 3 trials.
The announcement follows a flurry of news from other biotech and pharmaceutical companies this week that has fuelled expectations of a viable antidote and treatment for the pathogen sooner than later — as well as better methods for testing if people have it in the first place.
Moderna itself earlier this week said it had concluded advanced talks with the European Union to supply 80 million doses of mRNA-1273. As part of its final-stage trials, the company has enrolled 30,000 adults who are at high risk of contracting Covid-19. The trial is expected to be completed by Oct. 27.
Latest Videos From TheStreet and Jim Cramer:
- Coronavirus Update: Abbott's Fast $5 COVID-19 Test Gets FDA Emergency Use Authorization
- Salesforce Earnings Has Investors Really Excited About Software
- Jim Cramer’s Outlook on Oil Ahead of Hurricane Laura
- Big 12 Commissioner Explains Decision to Play College Sports to Jim Cramer
- McDonald’s Looking Into More Cover-Ups Under Former CEO’s Watch